Treating precancerous breast cells may prevent onset of cancer

October 17, 2002

Boston, MA (October 17, 2002) - Treating precancerous breast cells with chemopreventive agents, such as tamoxifen, limits the development of breast cancer in genetically predisposed women, according to a study presented at the American Association for Cancer Research's (AACR) annual Frontiers in Cancer Prevention meeting. Precancerous breast cells may also provide an effective mechanism for screening new and current chemopreventive agents.

The study used precancerous breast cells from patients with Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition syndrome associated with a number of childhood cancers and the early onset of breast cancer. Unlike most human cancer cells, LFS cells become cancerous at more measurable rates in vitro (a closed environment, e.g. test tube), and are therefore easier to monitor. Individuals with LFS are at increased risk for developing multiple primary cancers, including soft-tissue sarcoma, breast cancer, leukemia, osteosarcoma, melanoma and colorectal cancers.

"To effectively treat or prevent cancer, it is important to understand the nature of how cells progress into the disease," explained Brittney-Shea Herbert, Ph.D., cell biologist at The University of Texas Southwestern Medical Center, Dallas, and lead investigator of the study. "Results from human clinical trials take many years to generate so it is imperative that alternate testing forms, such as precancerous cells, be used to determine the effectiveness of precancerous agents."

Treatment of precancerous LFS breast cells with some but not all chemopreventive agents decreased the development of cancer in vitro. The chemopreventive agents used in this study did not negatively affect normal cell growth, nor result in notable side effects from the treatment. Tamoxifen had the strongest effect in preventing the frequency of cell immortalization, at nontoxic levels.

Precancerous cells were treated with tolerable levels of tamoxifen, nonsteriodal anti-inflammatory drugs (NSAIDS), a preoxisome proliferator-activated receptor ã (PPAR-ã) agonist, and the p53-rescue drug (CP31398), which reactivates the gene that suppresses tumor growth (p53). Treatment with CP31398 had the greatest effect in stopping the immortalization of cancer development, compared to the untreated or solvent controls. PPAR-ã agonist and CP31398 slowed the progression of the cancer; NSAIDS had a marginal effect, but it was not statistically significant. Immortalization is a critical step for cancer progression and validates the use of in vitro models.

More than 203,500 new cases of breast cancer will be diagnosed and more than 39,600 women will die in 2002, according to the American Cancer Society. Breast cancer is the second leading cause of cancer-death in women.
-end-
Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 19,000 laboratory and clinical scientists engaged in cancer research in the United States in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention).

American Association for Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.